Adial Pharmaceuticals Inc (ADIL)
1.01
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 16:00
1.08
+0.07
(+6.93%)
After-Hours: 04:30
Adial Pharmaceuticals Enterprise Value: 3.179M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 3.179M |
| November 01, 2024 | 3.179M |
| October 31, 2024 | 3.115M |
| October 30, 2024 | 3.086M |
| October 29, 2024 | 3.243M |
| October 28, 2024 | 3.372M |
| October 25, 2024 | 3.756M |
| October 24, 2024 | 3.756M |
| October 23, 2024 | 3.564M |
| October 22, 2024 | 4.204M |
| October 21, 2024 | 3.564M |
| October 18, 2024 | 3.179M |
| October 17, 2024 | 2.924M |
| October 16, 2024 | 3.308M |
| October 15, 2024 | 2.795M |
| October 14, 2024 | 2.939M |
| October 11, 2024 | 2.795M |
| October 10, 2024 | 2.795M |
| October 09, 2024 | 2.794M |
| October 08, 2024 | 2.782M |
| October 07, 2024 | 2.827M |
| October 04, 2024 | 2.930M |
| October 03, 2024 | 2.908M |
| October 02, 2024 | 2.798M |
| October 01, 2024 | 2.945M |
| Date | Value |
|---|---|
| September 30, 2024 | 3.109M |
| September 27, 2024 | 3.179M |
| September 26, 2024 | 3.117M |
| September 25, 2024 | 3.372M |
| September 24, 2024 | 3.436M |
| September 23, 2024 | 3.500M |
| September 20, 2024 | 3.436M |
| September 19, 2024 | 3.436M |
| September 18, 2024 | 3.628M |
| September 17, 2024 | 3.756M |
| September 16, 2024 | 3.692M |
| September 13, 2024 | 3.628M |
| September 12, 2024 | 3.692M |
| September 11, 2024 | 3.756M |
| September 10, 2024 | 3.179M |
| September 09, 2024 | 3.179M |
| September 06, 2024 | 3.115M |
| September 05, 2024 | 3.243M |
| September 04, 2024 | 3.372M |
| September 03, 2024 | 3.115M |
| August 30, 2024 | 2.994M |
| August 29, 2024 | 3.045M |
| August 28, 2024 | 2.885M |
| August 27, 2024 | 3.055M |
| August 26, 2024 | 3.500M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-1.463M
Minimum
Feb 26 2024
90.28M
Maximum
Sep 23 2021
17.50M
Average
8.874M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 9.837M |
| Theriva Biologics Inc | -12.61M |
| Oragenics Inc | 1.996M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.458M |
| Total Expenses (Quarterly) | 2.287M |
| EPS Diluted (Quarterly) | -0.59 |
| Earnings Yield | -506.4% |